Stevens Capital Management LP acquired a new position in shares of Qiagen N.V. (NASDAQ:QGEN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 35,555 shares of the company’s stock, valued at approximately $1,120,000.
Other institutional investors have also modified their holdings of the company. Fox Run Management L.L.C. purchased a new position in Qiagen N.V. during the 3rd quarter worth $753,000. Airain ltd purchased a new position in Qiagen N.V. during the 2nd quarter worth $1,390,000. Assenagon Asset Management S.A. purchased a new position in Qiagen N.V. during the 3rd quarter worth $10,110,000. Neuberger Berman Group LLC grew its position in Qiagen N.V. by 22.6% during the 2nd quarter. Neuberger Berman Group LLC now owns 1,349,457 shares of the company’s stock worth $45,247,000 after purchasing an additional 249,176 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in Qiagen N.V. during the 1st quarter worth $207,000. 60.47% of the stock is currently owned by institutional investors.
Several research firms have recently commented on QGEN. Deutsche Bank AG restated a “buy” rating on shares of Qiagen N.V. in a research note on Monday, July 31st. Barclays PLC restated an “overweight” rating and issued a $37.00 target price (up previously from $33.00) on shares of Qiagen N.V. in a research note on Monday, July 17th. TheStreet upgraded shares of Qiagen N.V. from a “c+” rating to a “b+” rating in a research note on Tuesday, November 7th. Zacks Investment Research cut shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Finally, Independent Research GmbH upgraded shares of Qiagen N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $34.06.
Shares of Qiagen N.V. (NASDAQ QGEN) opened at $30.77 on Tuesday. The company has a quick ratio of 4.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.68. Qiagen N.V. has a 52 week low of $27.51 and a 52 week high of $36.34. The company has a market cap of $7,180.41, a PE ratio of 25.64, a P/E/G ratio of 1.93 and a beta of 1.13.
Qiagen N.V. (NASDAQ:QGEN) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.32. Qiagen N.V. had a net margin of 6.40% and a return on equity of 11.36%. The firm had revenue of $364.00 million during the quarter, compared to analysts’ expectations of $363.42 million. During the same quarter last year, the business earned $0.29 earnings per share. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. research analysts forecast that Qiagen N.V. will post 1.25 EPS for the current fiscal year.
WARNING: “Stevens Capital Management LP Invests $1.12 Million in Qiagen N.V. (QGEN) Stock” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.truebluetribune.com/2017/11/14/stevens-capital-management-lp-invests-1-12-million-in-qiagen-n-v-qgen-stock.html.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.